Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Novacyt SA said Thursday that its has appointed David Allmond as chief executive officer following the decision by current CEO Graham Mullis to retire, effective from Oct. 18.
The clinical-diagnostics group, which is listed in London and Paris, said Mr. Allmond will bring significant experience in development and growth. He is currently chief business officer at Amryt Pharma PLC, and has previously held sales and marketing roles at Amgen Inc., Celgene Corp., and Aegerion Pharmaceuticals, Inc.
Mr. Mullis will continue to lead the company as CEO until Mr. Allmond joins the company to ensure a smooth transition, before retiring after 13 years with the wider business, Novacyt said.
"We look forward to working with [Mr. Allmond] and the recently strengthened senior management team to deliver on the company's strategy of organic, R&D and acquisitive growth that we recently reiterated at our full-year results," Chairman James Wakefield said.
Good days are ahead.
You should read the section titled "Risks and Uncertainties" in the 2021 annual report to gain an understanding of what you are investing in.
Summer doldrums - this always affects smaller cap stocks over the summer holiday period. The brave will buy. Expect to see them drift back up towards the end of August and into September..
Me too.
Took some off the table at £1.66 this morning..
You have a good attitude but don’t gamble for your sake, son.
Well I did learn one thing, don't trust the board, especially if they work for Amigo.
I didn't learn much in terms of Mathematics though which I think my question falls under!
No son, I'm here for the entertainment I do not invest in shares because I am not a gambler anymore.
I would have thought that your own 1,323 posts would have allowed you to learn something.
Am I wrong ?
3367 posts you must have learned enough to provide a reasonable response at least :-)
No son, there is no clever soul here at all.
Hi Folks,
Regarding this share swap - I can see the share prices have adjusted since the announcement, but am I right in thinking I'd actually be better off buying CHMA today?
Can any clever soul please explain the conversion to todays SP as it doesn't seem to make sense?
Tnx
Paps that old fart (:
I'm amazed at the lack of liquidity ..
Hi all, I’ve been holding these for a while and have topped up recently at 170 and again today at 175.
Im really hopeful about this business, I know there are some complications on the balance sheet but the existing products / turnover by themselves are positive and the pipeline looks diverse, deep and full of upside.
I find the lack of interest / liquidity pretty odd but “build it and they will come” seems applicable. The flip side is at least the chat isn’t full of agendas! Papillons perspectives are very valued and balanced - keep em coming.
Cheers!
All on holidays quiet weeks at the office.
https://finance.yahoo.com/news/chiasma-announces-submission-marketing-authorization-201200174.html
Interesting RNS - it looks like up until last Friday the market was not sure about the merger - hence the wrong price ratio between CHMA and AMYT. I guess the market got some inkling on Friday to believe it will happen, resulting in huge volumes on CHMA as the price adjusted to more closely reflect the correct ratio. Maybe AMYT is just rising based on more certainty about the buyout?
Correct joxer, something else this has been the trend for the last two years when something is progressing, small rises and then a sudden bigger rise.
Huge volume on CHMA yesterday - over 20% of the market cap. CHMA had been significantly undervalued based on the .396 conversion rate to AMYT. However, that doesn't account for the corresponding rise in AMYT. Something else going on here.
I'd wouldn't be surprised to see some chunky late reported trades..
Still don't think Chiasma was cheap cheap but a tablet as opposed to drip undoubtedly brings a better quality of life to patients.
CHMA and AMYT both moving now - some big trades on CHMA.
I bought a few here recently after selling a chunk of Open Orphan..
£5 would be nice if it reaches its $ target.
Cookie,
Amryt confirmed back in March that the EMA had accepted their MAA for review - so looks to be running ahead of the FDA application.
https://www.investegate.co.uk/amryt-pharma-plc/gnw/amryt-announces-validation-of-its-maa-by-the-ema-for-oleogel-s10---160--filsuvez--174--/20210329070000H4877/
The second smaller CVR is dependent on a positive opinion from the EMA application.....they submitted their application to the US for MAA but did they do the EU at the same time?